Calculate the infusion time for an IV of 1,500 mL running at 25 gtt/min. if the drop factor is 15 gtt/mL.

A. Aspirin and warfarin

The combination of aspirin and warfarin poses a potential risk of increased bleeding and bruising. Both aspirin and warfarin are anticoagulants, and when used together, they can potentiate each other's effects, leading to a higher risk of bleeding events, including easy bruising.

B. Sulfasalazine and acetaminophen

Sulfasalazine is often used in the treatment of arthritis and inflammatory bowel disease, while acetaminophen is a commonly used pain reliever. There is no significant interaction between these two medications leading to increased bleeding or bruising.

C. Tolmetin and propranolol

Tolmetin is a nonsteroidal anti-inflammatory drug (NSAID) used for pain relief, and propranolol is a beta-blocker used for conditions such as hypertension. While both medications have their own potential side effects, there is no specific interaction between them that significantly increases the risk of bleeding or bruising.

D. Meloxicam and amlodipine

Meloxicam is an NSAID, and amlodipine is a calcium channel blocker used for hypertension. Similar to option C, there is no known significant interaction between these two medications that would lead to increased bleeding or bruising.

A. As requested by the patient.

Administering the drug only when requested by the patient may not provide adequate prophylaxis against chemotherapy-induced nausea and vomiting. These medications are often prescribed on a schedule to prevent symptoms rather than treating them reactively.

B. 1 hour after chemotherapy administration.

Waiting until 1 hour after chemotherapy administration may not cover the full period during which nausea and vomiting are likely to occur. The administration schedule for antiemetics is often more extended to provide better coverage.

C. The night before the treatment, the day of the treatment, and for 24 hours after the treatment.

This is the correct choice. Administering phenothiazine antiemetics according to this schedule helps ensure continuous coverage during the critical period when chemotherapy-induced nausea and vomiting are most likely to occur.

D. The day of treatment.

Administering the drug only on the day of treatment may not provide sufficient coverage for the entire duration when chemotherapy-induced nausea and vomiting can occur. Again, the schedule mentioned in option C is more comprehensive for prevention.